Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription 06.10.2025 1 Am J Epidemiol 1 Am J Respir Cell Mol Biol 2 Ann Surg Oncol 3 Ann Thorac Surg 4 Anticancer Res 10 BMC Cancer 2 Br J Cancer 1 Cancer 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Lett 4 Cancer Sci 1 Chest 1 Clin Cancer Res 1 Clin Exp Metastasis 3 Clin Lung Cancer 5 Eur J Cancer 3 Eur J Cardiothorac Surg 1 Int J Cancer 5 Int J Radiat Oncol Biol Phys 2 J Clin Oncol 1 J Immunol 3 J Thorac Cardiovasc Surg 2 JAMA Oncol 2 Lancet Oncol 8 Lung Cancer 2 Mol Cancer Ther 2 N Engl J Med 2 Oncologist 4 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Epidemiol

1. ZHOU W, Mucci LA, Song M, Shen H, et al
   Pre-diagnostic Body Mass Index Trajectories and Associations with Lung Cancer Risk.
   Am J Epidemiol. 2025 Oct 1:kwaf084. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Am J Respir Cell Mol Biol

2. CHEN W, Baldoni PL, Zhou AX
   From Splicing Landscape to Therapeutic Targets: Long-Read Sequencing in Non-Small-Cell Lung Cancer.
   Am J Respir Cell Mol Biol. 2025 Sep 25. doi: 10.1165/rcmb.2025-0483.
   PubMed        
   
   

   
   Ann Surg Oncol

3. MOTT NM, Meguid RA, Stuart CM
   ASO Author Reflections: Social Vulnerability and Surgical Delay in Resectable Non-small Cell Lung Cancer.
   Ann Surg Oncol. 2025 Sep 29. doi: 10.1245/s10434-025-18464.
   PubMed        
   
   
4. LI Z, Yang Z, Liu C
   Induction Therapy with Crizotinib Before Surgery for ROS1 Fusion-Positive Potentially Resectable Non-small Cell Lung Cancer.
   Ann Surg Oncol. 2025 Sep 27. doi: 10.1245/s10434-025-18402.
   PubMed        
   
   

   
   Ann Thorac Surg

5. HINES SE, Dement J, Ringen K
   Occupational Risk: A Gap in Lung Cancer Screening Guidelines.
   Ann Thorac Surg. 2025 Sep 30:S0003-4975(25)00903.
   PubMed        
   
   
6. QU R, Fu X
   Occult N1 Non-Small Cell Lung Cancer: Why We Need Caution Before Embracing Segmentectomy as Standard.
   Ann Thorac Surg. 2025 Sep 30:S0003-4975(25)00905.
   PubMed        
   
   
7. LEE J, Hong YS, Lee J, Lee G, et al
   Clinical N Staging Subclassification for Stage III-N2 NSCLC Patients Undergoing Trimodality Therapy: A Good Beginning Is Half the Battle.
   Ann Thorac Surg. 2025;120:665-673.
   PubMed         Abstract available
   
   

   
   Anticancer Res

8. SEONG H, Kim SH, Kim MH, Eom JS, et al
   Prognostic Impact of ALK Rearrangements in Resected NSCLC: A Systematic Review and Meta-analysis.
   Anticancer Res. 2025;45:4519-4534.
   PubMed         Abstract available
   
   
9. NAKAO M, Kuriyama M, Hasegawa M, Gomyo R, et al
   Albumin-based Liver Reserve Models as Prognostic Markers for Patients With Extensive-stage Small-cell Lung Cancer.
   Anticancer Res. 2025;45:4483-4491.
   PubMed         Abstract available
   
   
10. OGASAWARA M, Miyashita M, Yamagishi Y, Ota S, et al
    Prognostic Impact of PD-1 Polymorphisms in Non-small Cell Lung Cancer Receiving Dendritic Cell Vaccination.
    Anticancer Res. 2025;45:4295-4304.
    PubMed         Abstract available
    
    
11. NAKAJIMA Y, Kuribayashi K, Tada A, Nagano A, et al
    Combined Compression and Cooling Therapy for Taxane Chemotherapy-induced Peripheral Neuropathy in Lung Cancer.
    Anticancer Res. 2025;45:4373-4380.
    PubMed         Abstract available
    
    

    
    BMC Cancer

12. KATSUSHIMA U, Fukushima T, Nakano J, Fujii K, et al
    Combined effects of slow movement training with tonic force generation and aerobic exercise prior to cancer therapy in patients with lung cancer (START-lung): a pilot feasibility trial.
    BMC Cancer. 2025;25:1438.
    PubMed         Abstract available
    
    
13. HUANG Y, Yuan X, Xu L, Jian J, et al
    Automated contouring of gross tumor volume lymph nodes in lung cancer by deep learning.
    BMC Cancer. 2025;25:1444.
    PubMed         Abstract available
    
    
14. QIN L, Zhao L, Li XM, Jia QC, et al
    A CT-based radiomics nomogram incorporating adipose tissue to differentiate invasive adenocarcinomas among part-solid pulmonary nodules.
    BMC Cancer. 2025;25:1471.
    PubMed         Abstract available
    
    
15. OBATA T, Norikane T, Manabe Y, Murao M, et al
    Torso FDG-PET parameters as prognostic biomarkers for advanced non-small cell lung cancer patients undergoing first-line immunotherapy and chemotherapy.
    BMC Cancer. 2025;25:1454.
    PubMed         Abstract available
    
    
16. ZHONG J, Han X, Lofters A, Singh J, et al
    Lung cancer stage at diagnosis and immigrant English/French language proficiency: a retrospective population level cohort study of urban residents in Ontario, Canada.
    BMC Cancer. 2025;25:1452.
    PubMed         Abstract available
    
    
17. BOLEK H, Kayaalp M, Sahin TK, Dogan OT, et al
    Real-world treatment patterns and survival outcomes in metastatic head and neck adenoid cystic carcinoma.
    BMC Cancer. 2025;25:1451.
    PubMed         Abstract available
    
    
18. YANG X, He Y, Guo T, Fang J, et al
    The efficacy analysis of neoadjuvant chemoimmunotherapy followed by surgery in stage III locally advanced non-small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:1443.
    PubMed         Abstract available
    
    
19. CHEN X, Xiao X, Wang M, Mei T, et al
    Development and validation of a dynamic nomogram for predicting brain metastasis in stage III NSCLC patients undergoing definitive chemoradiotherapy.
    BMC Cancer. 2025;25:1500.
    PubMed         Abstract available
    
    
20. WEN J, Yun W, Yin X, Meng X, et al
    Effect of tumor draining lymph nodes in the formation and maturation of tertiary lymphoid structure in patients with lung adenocarcinoma.
    BMC Cancer. 2025;25:1507.
    PubMed         Abstract available
    
    
21. WANG K, An L, Zang A, Huo Y, et al
    Chidamide impedes glycolysis but increases ferroptosis and cisplatin sensitivity of lung cancer cells through downregulating USP35.
    BMC Cancer. 2025;25:1504.
    PubMed        
    
    

    
    Br J Cancer

22. RUBIO-SAN-SIMON A, Wilson W, Sironi G, le Deley MC, et al
    Prognostic factors in patients with relapsed high-grade osteosarcoma: a systematic review.
    Br J Cancer. 2025;133:1020-1028.
    PubMed         Abstract available
    
    
23. JING P, Liang Y, Tan Z, Yan X, et al
    Physiological and psychological symptom management based on electronic patient-reported outcomes: the TD-WELLBEING randomized clinical trial.
    Br J Cancer. 2025;133:937-944.
    PubMed         Abstract available
    
    

    
    Cancer

24. NIERENGARTEN MB
    Therapies for patients with previously treated lung cancer: Two second-line therapies receive accelerated approval for treatment.
    Cancer. 2025;131:e70076.
    PubMed        
    
    

    
    Cancer Epidemiol Biomarkers Prev

25. HOLOWATYJ AN, Liu L, Munro HM, Perkins-Smith JJ, et al
    Income, Race, and Survival among Low-Income Black and White Americans with Lung, Breast, Prostate, or Colorectal Cancer.
    Cancer Epidemiol Biomarkers Prev. 2025;34:1749-1758.
    PubMed         Abstract available
    
    

    
    Cancer Lett

26. JIA W, Ma L, Bai M, Li J, et al
    Loss of ADAR1 in lung cancer activates anti-tumour immunity and suppresses tumour cell growth via the RIG-I/MDA5-MAVS pathway.
    Cancer Lett. 2025 Sep 30:218071. doi: 10.1016/j.canlet.2025.218071.
    PubMed         Abstract available
    
    

    
    Cancer Sci

27. TAKAOKA H, Terai H, Nakamura K, Mizuno T, et al
    Clinical Application of In-House Comprehensive Genomic Profiling for Thoracic Cancer: Insights From a Japanese Hospital.
    Cancer Sci. 2025;116:2819-2830.
    PubMed         Abstract available
    
    
28. TERASHIMA Y, Park S, Ikeuchi H, Hayashi T, et al
    Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
    Cancer Sci. 2025;116:2868-2881.
    PubMed         Abstract available
    
    
29. NGUYEN TTN, Chen PY, Zheng MY, Lin TK, et al
    Intrinsic PDL1 Signaling Modulates TGFBI-Mediated Growth Suppression in Lung Adenocarcinoma.
    Cancer Sci. 2025;116:2737-2749.
    PubMed         Abstract available
    
    
30. ZHANG Z, Wang C, Guo Y, Zhao Z, et al
    HROB Induces Lung Adenocarcinoma Progression via ZC3HC1-CCNB1 Axis Regulation and Cell Cycle Dysregulation.
    Cancer Sci. 2025;116:2699-2711.
    PubMed         Abstract available
    
    

    
    Chest

31. PRADERE P, Marinello A, Vasseur D, Naltet C, et al
    The impact of dual cannabis and tobacco smoking in young patients with lung cancer: results from the prospective "Environment and Lung Cancer" study.
    Chest. 2025 Sep 24:S0012-3692(25)05378-4. doi: 10.1016/j.chest.2025.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

32. GIUDICE AM, Matlaga S, Roth SL, Gladney W, et al
    D3-GPC2-directed CAR T cells are safe and efficacious in preclinical models of neuroblastoma and small cell lung cancer.
    Clin Cancer Res. 2025 Sep 30. doi: 10.1158/1078-0432.CCR-25-0089.
    PubMed         Abstract available
    
    

    
    Clin Exp Metastasis

33. ZIEGLER DA, Ambold M, Schirmer MA, Droge LH, et al
    The abscopal effect in metastatic lung cancer: a retrospective analysis of combined radiotherapy and immunotherapy.
    Clin Exp Metastasis. 2025;42:56.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

34. ALAPARTHI SS, Ishwar A, Whitehorn G, Madeka I, et al
    Is Lobectomy Associated With Improved Outcomes Compared to Segmentectomy in Small Cell Lung Cancer Discovered at the Time of Resection?
    Clin Lung Cancer. 2025 Aug 29:S1525-7304(25)00224.
    PubMed         Abstract available
    
    
35. LUBAS MJ, Vata A, Fredette J, Edelman MJ, et al
    An Institution-Specific Hypofractionated Radiation Therapy Regimen in the Treatment of Central and Ultracentral Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2025 Sep 1:S1525-7304(25)00225.
    PubMed         Abstract available
    
    
36. ZHOU H, Liang B, Lu LC, Chan CP, et al
    Characteristics of Epidermal Growth Factor Receptor-Mutant Nonsmall-Cell Lung Cancer Patients Benefiting From Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Clin Lung Cancer. 2025 Aug 27:S1525-7304(25)00199.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

37. MERCOLINI F, Sparber-Sauer M, Mascarenhas L, Merks JHM, et al
    Single site metastatic rhabdomyosarcoma: An INternational Soft Tissue saRcoma ConsorTium (INSTRuCT) pooled analysis.
    Eur J Cancer. 2025;229:115793.
    PubMed         Abstract available
    
    
38. LIU Y, Wang L, Li L, He L, et al
    Comment on: "A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer".
    Eur J Cancer. 2025;230:115801.
    PubMed        
    
    
39. BYUN JY, Kim J, Park S, Sun JM, et al
    A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer.
    Eur J Cancer. 2025;230:115805.
    PubMed         Abstract available
    
    
40. PRABHASH K, Noronha V, Patil V, Menon N, et al
    Response to Letter Re: "A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer".
    Eur J Cancer. 2025;230:115802.
    PubMed        
    
    
41. WEBENDOERFER M, Wiesweg M, Winantea J, Keyl J, et al
    Early years, advanced disease: The unmet need in young adults with non-small cell lung cancer.
    Eur J Cancer. 2025;230:116011.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

42. LEE JO, Lee GD, Choi S, Kim HR, et al
    Beyond the Lung: Distinct Recurrence Patterns of Mucinous and Non-mucinous Lung Adenocarcinoma After Surgery.
    Eur J Cardiothorac Surg. 2025;67:ezaf282.
    PubMed         Abstract available
    
    
43. LEI Z
    "Data or Distraction?" Reassessing the Conclusions on Resident Involvement in Lung Cancer Surgery.
    Eur J Cardiothorac Surg. 2025 Sep 25:ezaf323. doi: 10.1093.
    PubMed        
    
    
44. SUZUKI S, Asakura K, Masai K, Kaseda K, et al
    Real-World outcomes of limited resection for tumors greater than 20 mm in non-small cell lung cancer.
    Eur J Cardiothorac Surg. 2025 Sep 29:ezaf322. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Int J Cancer

45. YOSHIKAWA R, Watanabe T, Ohtaki Y, Bando T, et al
    Novel therapeutic strategy targeting STMN1 using chlorambucil-conjugated pyrrole-imidazole polyamide in small cell lung cancer.
    Int J Cancer. 2025 Sep 30. doi: 10.1002/ijc.70179.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

46. MEHTA MP, Gondi V, Ahluwalia MS, Roberge D, et al
    Tumor Treating Fields (TTFields) therapy after stereotactic radiosurgery for brain metastases from non-small cell lung cancer: final results of the phase 3 METIS study.
    Int J Radiat Oncol Biol Phys. 2025 Sep 29:S0360-3016(25)06217.
    PubMed         Abstract available
    
    
47. DANG A, Palma DA, Wang E, Lang P, et al
    Dosimetric Outcomes for Stereotactic Radiotherapy in Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Secondary Analysis of the ASPIRE-ILD Trial.
    Int J Radiat Oncol Biol Phys. 2025 Sep 29:S0360-3016(25)06288.
    PubMed         Abstract available
    
    
48. LI Q, Ma H, Zheng R, Cai L, et al
    Durvalumab combined with chemotherapy and Stereotactic Ablative Body Radiotherapy (SABR) in patients with oligometastatic non-small cell lung cancer: a multi-center phase 2 study.
    Int J Radiat Oncol Biol Phys. 2025 Sep 24:S0360-3016(25)06304.
    PubMed         Abstract available
    
    
49. ARCIDIACONO F, Anselmo P, Casale M, Zannori C, et al
    5-year survival and safety of stereotactic ablative radiotherapy in unresectable locally advanced non-small cell lung cancer patients unfit for concurrent radio-chemotherapy:focus on patterns of local recurrence from the START-NEW-ERA non-randomized p
    Int J Radiat Oncol Biol Phys. 2025 Sep 22:S0360-3016(25)06209.
    PubMed         Abstract available
    
    
50. CORN BW, Paulus R, Gondi V, Mehta MP, et al
    "Hope" Drives Quality of Life in Patients with Brain Metastases, But, the "Hope Center" Remains Elusive: An Analysis of NRG-CC003.
    Int J Radiat Oncol Biol Phys. 2025 Jul 2:S0360-3016(25)04519.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

51. ZHANG Y, Qian B, Song Q, Ma J, et al
    Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity-Dominant Lung Adenocarcinoma.
    J Clin Oncol. 2025;43:3081-3089.
    PubMed         Abstract available
    
    
52. CHAUNZWA TL, Jabbour SK, Pike LRG, Cooper AJ, et al
    Bridging the Gap: The Evolving Landscape of CNS Management in Small Cell Lung Cancer: Prophylactic Cranial Irradiation in the Modern Era.
    J Clin Oncol. 2025 Sep 26:JCO2501817. doi: 10.1200/JCO-25-01817.
    PubMed        
    
    

    
    J Immunol

53. WANG S, Li F, Zhang L, Ping Y, et al
    HMGB1 inhibits the IFN-gamma-induced PD-L1 expression in NSCLC.
    J Immunol. 2025;214:2480-2488.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

54. BUI J, Kalata S, Reddy RM, Clark M, et al
    An evaluation of lymph node harvest in sublobar resections in a statewide quality collaborative.
    J Thorac Cardiovasc Surg. 2025;170:915-923.
    PubMed         Abstract available
    
    
55. GOMES C, Cowan B, Xiao M, Morris P, et al
    Diagnostic effectiveness and safety of robotic-assisted bronchoscopy for subsolid pulmonary nodules: A multicenter prospective observational study.
    J Thorac Cardiovasc Surg. 2025;170:945-954.
    PubMed         Abstract available
    
    
56. ALTORKI N, Damman B, Wang X, Liberman M, et al
    The extent of lymph node dissection is not associated with disease-free survival following lobar or sublobar resection: Results from Cancer and Leukemia Group B 140503 (Alliance).
    J Thorac Cardiovasc Surg. 2025;170:933-942.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

57. ANTONOFF MB, Phillips L, Singhi EK
    Understanding Lung Cancer in Younger People.
    JAMA Oncol. 2025 Sep 25. doi: 10.1001/jamaoncol.2025.3320.
    PubMed        
    
    
58. LIN JK, Xu Y, Xiang JJ, Singhi EK, et al
    Nationwide Response to Carboplatin and Cisplatin Shortages in Lung Cancer.
    JAMA Oncol. 2025 Oct 2:e253768. doi: 10.1001/jamaoncol.2025.3768.
    PubMed        
    
    

    
    Lancet Oncol

59. DI FEDERICO A, Wang K, Chen MF, Barsouk AA, et al
    First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF(V600E)-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study.
    Lancet Oncol. 2025;26:1357-1369.
    PubMed         Abstract available
    
    
60. DI FEDERICO A, Stumpo S, Mantuano F, De Giglio A, et al
    Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis.
    Lancet Oncol. 2025 Sep 29:S1470-2045(25)00429.
    PubMed         Abstract available
    
    

    
    Lung Cancer

61. ZHANG C, Wang W, Bi N, Wang J, et al
    Efficacy and safety of consolidative thoracic radiotherapy for Extensive-Stage Small-Cell lung cancer in the era of immunotherapy: A Real-World study.
    Lung Cancer. 2025;208:108758.
    PubMed         Abstract available
    
    
62. PIERRET T, Greillier L, Guisier F, Daniel C, et al
    Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study.
    Lung Cancer. 2025;209:108766.
    PubMed         Abstract available
    
    
63. ISLA D, Zugazagoitia J, Arriola E, Garcia-Campelo R, et al
    Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial.
    Lung Cancer. 2025;209:108763.
    PubMed         Abstract available
    
    
64. HAMADA S, Tomita Y, Fujino K, Miyashita A, et al
    Association of lung silica deposition with epidermal growth factor receptor-mutant lung cancer.
    Lung Cancer. 2025;209:108767.
    PubMed         Abstract available
    
    
65. REALE ML, Scattolin D, Vitale A, Passiglia F, et al
    Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database.
    Lung Cancer. 2025;209:108762.
    PubMed         Abstract available
    
    
66. WEBSTER L, Lawton S, Kipps E, Thackray K, et al
    Durvalumab in locally advanced unresectable non-small cell lung cancer - Benchmarking real-world outcomes in England against published trial data.
    Lung Cancer. 2025;209:108752.
    PubMed         Abstract available
    
    
67. SUGATA K, Aokage K, Taki T, Nomura K, et al
    Impact of tumor cell burden beyond the elastic layer on prognosis in T2aN0M0 non-small cell lung cancer with visceral pleural invasion.
    Lung Cancer. 2025;208:108759.
    PubMed         Abstract available
    
    
68. GURNEY J, Ongley D, Cameron L, Costello S, et al
    Patterns of treatment prior to death among those with lung cancer: A national study in a universal healthcare context.
    Lung Cancer. 2025;208:108761.
    PubMed         Abstract available
    
    

    
    Mol Cancer Ther

69. DENG S, Hussain T, Bartelli TF, Sebastian MM, et al
    Repurposing of the Macrolide Antibiotic Clarithromycin for the Prevention of Lung Cancer.
    Mol Cancer Ther. 2025 Sep 30. doi: 10.1158/1535-7163.MCT-25-0392.
    PubMed         Abstract available
    
    
70. PATEL UA, Shi MY, Kazan JM, Nixon KCJ, et al
    CRISPR Screen Identifies HDAC3 as a Novel Radiosensitizing Target in Small Cell Lung Cancer.
    Mol Cancer Ther. 2025 Sep 25:OF1-OF13. doi: 10.1158/1535-7163.MCT-24-0861.
    PubMed         Abstract available
    
    

    
    N Engl J Med

71. YILDIZ O, Araz M
    Tarlatamab in Small-Cell Lung Cancer.
    N Engl J Med. 2025;393:1348.
    PubMed        
    
    
72. RUDIN CM, Mountzios G
    Tarlatamab in Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2025;393:1348-1349.
    PubMed        
    
    

    
    Oncologist

73. CHEN G, Zhu J, Jian C, Chen X, et al
    Efficacy and safety of Rh-endostatin in the treatment of radiation pneumonitis in non-small cell lung cancer.
    Oncologist. 2025 Sep 27:oyaf318. doi: 10.1093.
    PubMed         Abstract available
    
    
74. LIU Y, Li X, Zhang M, Gao Y, et al
    A cohort study of circulating biomarkers to predict the efficacy and prognosis of immune combination therapy in non-small cell lung cancer.
    Oncologist. 2025 Sep 25:oyaf306. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    PLoS One

75. LANG W, Wang J, Ouyang M, Zhao H, et al
    Cost-effectiveness analysis of benmelstobart and anlotinib plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: Perspectives from the United States and China.
    PLoS One. 2025;20:e0331338.
    PubMed         Abstract available
    
    
76. QIU X, Hu S, Dong S, Sun H, et al
    Construction of an automated machine learning-based predictive model for postoperative pulmonary complications risk in non-small cell lung cancer patients undergoing thoracoscopic surgery.
    PLoS One. 2025;20:e0333413.
    PubMed         Abstract available
    
    
77. ABOALHAIJA N, Abulawi H, Hamed R, Alwahsh M, et al
    Phytochemical characterization, anticancer potential, and nanoemulsion-based delivery of Chiliadenus montanus.
    PLoS One. 2025;20:e0333482.
    PubMed         Abstract available
    
    
78. XIAO Y, Lin X, Gong H, Hu J, et al
    The association of POSTN with postoperative recurrence risk in early-stage lung adenocarcinoma: From gene networks to cellular functions.
    PLoS One. 2025;20:e0331590.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

79. CHEN S, Zhong M, Wang X, Su Y, et al
    Activation of epigenetic reprogramming via crotonylation overcomes resistance to EGFR-TKI therapy in lung cancer.
    Proc Natl Acad Sci U S A. 2025;122:e2509255122.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.